1、AloxistatinCat. No.: HY-100229CAS No.: 88321-09-9Molecular Formula: CHNOMolecular Weight: 342.43Target: CathepsinPathway: Metabolic Enzyme/ProteaseStorage: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 monthSolvent 74(10):4894-7.2. Konjar S, et al. Human and mouse perforin are processe
2、d in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology. 2010 Oct;131(2):257-67.3. Mullins SR, et al. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem. 2012 Dec;393(12):1405-16.4. Hoo
3、k G, et al. The cysteine protease inhibitor, E64d, reduces brain amyloid- and improves memory deficits in Alzheimers disease animal models by inhibiting cathepsin B, but not BACE1, -secretase activity. J Alzheimers Dis. 2011;26(2):387-408.5. Cheng XW, et al. Superoxide-dependent cathepsin activation
4、 is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008 Aug;173(2):358-69.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Environ Sci Technol. 2017 Dec 5;51(23):13938-13948. Toxicol Appl Pharmacol. 2018 Aug 4;356:159-171. Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303.www.MedChemE3
